Moderna to construct science center in Cambridge, MA
Will feature laboratories intended for R&D
People spotlight — September 2021
The latest people news happenings over the past month
New temperature indicator targets vaccine wastage
Can monitor vials for temperature breaches at any point in cold chain, developer says
Genentech, Lifelink Systems form patience experience partnership
Collaboration centers around providing assistance to multiple links in the clinical trial chain, from participants to providers
Siemens Healthineers plans to invest over $32M in site expansion
Development of additional 29,000 square feet addresses med tech company’s internal production capabilities
Biosimilars gain traction with regulators, manufacturers
Recent FDA actions may finally usher in access boost to follow-on biologics in the US
AstraZeneca invests in self-amplifying RNA
R&D partnership with VaxEquity outlines plan to use saRNA as a go-to therapeutic
Maersk to debut carbon neutral pharma warehouse
Polish facility will be based on GDP and ISO practices
AstraZeneca to invest $360M in API manufacturing plant
Financial commitment expected to expand the development and commercialization pipeline for new medicines
Tower Cold Chain Solutions opens new headquarters
UK location offers close proximity to London Heathrow Airport
Pfizer-BioNTech vaccine trial presents positive results in children ages 5-11 years old
Side effects were consistent with 16-25 age group
Health Canada approves Pfizer, Moderna Covid vaccines in individuals 12 and older
Both Comirnaty, Spikevax jabs had previously been authorized for use under Interim Order
Catalent and Phathom Pharmaceuticals sign commercial supply agreement
Deal is dependent on FDA approval of Phathom’s vonoprazan compound
JLL Life Sciences Real Estate Outlook: Boom times continue for Boston metro area
Availability of space for new labs is a key selling point
Syneos Health purchases StudyKIK
Acquisition expected to help provide customers with a quicker clinical trial recruitment process
Emergent, Providence Therapeutics ink vaccine manufacturing agreement
Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot
AGC Biologics grows pDNA, mRNA production abilities at Heidelberg site
Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions
Thermo Fisher to build Nashville single-use technology manufacturing site
Latest construction plan continues CDMO’s vision for biopharma expansion
HDA calls for withdrawal of FDA’s latest DSCSA guidance on the ‘enhanced drug distribution system’
FDA’s recommended guidance is for a system that ‘does not exist, cannot be built by 2023, and poses unacceptable security and compliance risks,’ says alliance
Report: BioNTech to seek vaccine approval for 5 to 11-year-olds over the ‘next few weeks’
Biotech firm to file regulatory dossier with officials around the world
Olon to expand Settimo Torinese location, as company adds protein production to repertoire
CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand
Adaptimmune Therapeutics, Genentech partner up to support allogeneic cell therapy development and commercialization
Collaboration earns Adaptimmune an initial payday of $150 million
USAntibiotics reopens Tennessee production facility
After previously going bankrupt, center is now under US ownership for the first time
Japan to purchase 150 million doses of Novavax’s Covid vaccine
Supply deal with Takeda to begin distribution in early 2022, pending shot approval
AstraZeneca, EU reach Covid vaccine supply settlement
Drug maker to supply European Union with 60 million doses by end of Q3
IQVIA unveils contact center powered by AI
Objective is to provide efficiency for analytics company’s medical information department
New CDMO, ten23 health, joins the biopharma industry
Swiss organization will take patient-centric approach towards developing injectables
BioNTech plans to launch mRNA vaccine manufacturing in Africa
Company’s prospective malaria and tuberculosis doses will be developed in Rwanda, Senegal
BioDuro-Sundia acquires drug product manufacturing facility
Irvine, CA, location will house 40,000 square feet of oral solid dosage forms
Cipla, Kemwell ink biosimilars joint venture
Agreement will focus on developing, manufacturing and commercializing biosimilars in the respiratory space
